Tagala, Severina .
HRN: 11-87-29 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/14/2025
CO-AMOXICLAV 625MG (TAB)
06/14/2025
06/17/2025
PO
625 Mg/tab
TID
Pneumonia
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes